Breaking Finance News

Mizuho Securities announced Adamas Pharmaceuticals (NDAQ:ADMS), boosting its stock price target to $48.00 today

Yesterday Adamas Pharmaceuticals (NDAQ:ADMS) traded -1.90% lower at $21.42. The company’s 50-day moving average is $18.10 and its 200-day moving average is $17.19. The last stock close price is up 22.83% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 967,377 shares of the stock were exchanged, up from an average trading volume of 758,283

In a statement issued on Tuesday September 19, 2017 Mizuho Securities bumped up the target of Adamas Pharmaceuticals (NDAQ:ADMS) from $26.00 to $48.00 stating a possible upside of 1.24%.

Previously on 08/25/2017, JMP Securities reported about Adamas Pharmaceuticals (NDAQ:ADMS) raised the target price from $29.00 to $33.00. At the time, this indicated a possible upside of 0.63%.

See Chart Below

Adamas Pharmaceuticals (NDAQ:ADMS)

Adamas Pharmaceuticals has a 52 week low of $12.10 and a 52 week high of $22.58 The company’s market cap is currently $0.

In addition to Mizuho Securities reporting its stock price target, a total of 8 analysts have released a research note on Adamas Pharmaceuticals. The 12-month price target is $36.00 with zero brokerages rating the company a strong buy, zero equity analysts rating the company a buy, zero equity analysts rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Adamas Pharmaceuticals (NDAQ:ADMS)

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.